Prosecution Insights
Last updated: November 12, 2026
Application No. 18/670,160

METHODS FOR TREATING ADRENAL GLAND TUMORS

Non-Final OA §103§112§DP
Filed
May 21, 2024
Priority
May 22, 2023 — provisional 63/468,082
Examiner
MARTIN, KEVIN STEPHEN
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Corcept Therapeutics Incorporated
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
98%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
124 granted / 161 resolved
+17.0% vs TC avg
Strong +21% interview lift
Without
With
+20.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
52 currently pending
Career history
203
Total Applications
across all art units

Office Action

§103 §112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims The claims filed May 21, 2024 are acknowledged and entered. Claims 1-22 are pending. Priority This application is claims benefit of 63/468,082, filed May 22, 2023. Information Disclosure Statement Acknowledgement is made of the Information Disclosure Statements filed on July 10, 2024; December 13, 2024; and March 4, 2026. All references have been considered except where marked with a strikethrough. Specification The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any of the errors of which applicant may become aware of in the specification. Election/Restriction The election of species requirement mailed July 2, 2026 has been reconsidered and is hereby withdrawn. Claim Objections Claims 1 and 11 are objected to for reciting improper Markush language. Proper Markush language requires singular and alternative language, such as, "A compound of formula (I) or a pharmaceutically acceptable salt thereof." In the present case the claims recite “salts and isomers” and it is suggested the claim be amended to recite “salt or…”. Claim Rejections - 35 USC § 112b The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-22 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims are indefinite for the reasons that follow: A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claims 1 and 11 recite the broad recitation “reducing a dimension”, and the claims also recite “reducing the size”, “reducing the volume”, “reducing the weight”, “reducing the mass” which are the narrower statement of the range/limitation. “Size”, “volume”, “weight” and “mass” are all different dimensions and thus embraced by the broader recitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claims 1 and 11 recite the phrase “GRM comprises”. “GRM comprises” renders the scope of the claims indefinite because it is not clear what other elements are intended to be included in the GRM other than formula (I). The transitional term "comprising", which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. See MPEP 2111.03. It appears from the specification that GRM is intended to be a compound (see e.g. [0009] and [0010]). It is suggested Applicant amend the claim to recite “GRM having…structure of formula (I)”. Claims 1 and 11 recite the term “isomers” which renders the scope formula (I) indefinite because the specification provides no definition of which “isomers” are intended. Isomer is a generic term embracing all forms of isomer including constitutional isomers which includes compounds that have an entirely different atom connectively than formula (I). Based on the disclosure a person skilled in the art has no way of knowing the scope of compounds embraced by formula (I). It is suggested the claim be amended to delete “isomers”. Claims 2-10 and 12-22 depend from claims 1 or 11, do not cure the abovementioned deficiencies, and therefore are also indefinite. Regarding claims 10 and 20, the phrase "e.g., low bone density…" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-22 are rejected under 35 U.S.C. 103 as being unpatentable over Greenstein et al. (WO2021/154750 A1)(hereinafter “Greenstein”). Regarding claims 1-2 and 11-12, Greenstein teaches a method of reducing the load of an adrenal gland tumor (adrenocortical carcinoma, ACC) comprising administration of a glucocorticoid receptor modulator (GRM) wherein the GRM is relacorilant (see claim 1, adrenocortical carcinoma, see claim 10). Greenstein teaches the method reduces tumor size (see [0222] ). As evidenced by Del Rivero et al. (Front Endocrinol 2022 13, 961650, Abstract), ACC is an adrenal gland tumor (Abstract: ACC is a rare endocrine malignancy of the adrenal gland). Regarding claims 3-4 and 13-14, Greenstein teaches wherein the GRM may be administered orally (see [0011]). Oral administration would include administration with food. Regarding claims 5, 7, 9-10, 15, 17 and 19-20, Greenstein teaches ACC patients with cortisol excess experience Cushing’s Syndrome (see [0258]). Cortisol excess would be the result of the adrenal gland tumor, ACC, secreting cortisol. A patient who experiences cortisol excess would be suffering from abnormally high blood levels of cortisol. Regarding claims 6 , 7, 16 and 17, Greenstein teaches administration of the elected compound in the treatment of an adrenal gland tumor. The method of Greenstein would necessarily include wherein the GRM is effective to reduce secretion of cortisol and wherein treatment is effective to reduce cortisol blood levels as these are no more than downstream effects that result from administering the compound. Regarding claim 8 and 18, Greenstein teaches cortisol levels vary during the course of the day and night and that cortisol excess is associated with cancer wherein ACC patients experience systemic excess (see [0001]-[0002]). Such a patient would lack an appropriate diurnal rhythm in their cortisol levels. Regarding claims 20-21, Greenstein teaches the tumor may be benign (see [0042]). The difference between Greenstein and the instant claims is that the instant claims recite an adrenal gland tumor. However, the claimed invention would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention because ACC is an adrenal gland tumor. One would have been motivated as a matter of treating ACC. One would have had a reasonable expectation of success because the claimed method was already known to be useful for the treatment of an adrenal gland tumor. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 11,464,764, claim 1 of U.S. Patent No. 11,925,626, or claim 1 of U.S. Patent No. 12,514,849 in view of Greenstein et al. (WO2021/154750 A1)(hereinafter “Greenstein”). Each of the patent claims is drawn to a formulation for oral administration of relacorilant (patent claim 1 of US12,514,849 pictured below) PNG media_image1.png 248 262 media_image1.png Greyscale The patent claims are silent regarding a method of reducing the size of an adrenal gland tumor; however, Greenstein teaches that relacorilant may be used in a method of reducing the size of an adrenal gland tumor, and Greenstein provides all claim limitations as was noted in the rejection above. The teachings of Greenstein are incorporated herein by reference. The difference between the patent claims and the instant claims is that the instant claims are drawn to a method of using the patented formulation for reducing the size of an adrenal gland tumor. However, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the instant applicant to use the patented invention in a method as is claimed because Greenstein had already disclosed that the compound was useful for this purpose. One would have been motivated as a matter of practicing the patented invention. One would have had a reasonable expectation of success because relacorilant was already known to be useful in a method of reducing the size of an adrenal gland tumor. Claims 1-22 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of copending Application No. 19/408,669 (reference application) in view of Greenstein et al. (WO2021/154750 A1)(hereinafter “Greenstein”). The reference claim is drawn to a formulation for oral administration of relacorilant. The reference claims are silent regarding a method of reducing the size of an adrenal gland tumor; however, Greenstein teaches that relacorilant may be used in a method of reducing the size of an adrenal gland tumor, and Greenstein provides all claim limitations as was noted in the rejection above. The teachings of Greenstein are incorporated herein by reference. The difference between the reference claim and the instant claims is that the instant claims are drawn to a method of using the formulation of the reference claim for reducing the size of an adrenal gland tumor. The instant claims would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention for the reasons set forth above in the rejection over U.S. Patent No. 11,464,764, U.S. Patent No. 11,925,626, or U.S. Patent No. 12,514,849 in view of Greenstein and which are incorporated herein by reference. This is a provisional nonstatutory double patenting rejection. Claims 1-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of U.S. Patent No. 12,648,943. Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims are obvious over the patent claims. Patent claim 1 recites: PNG media_image2.png 330 258 media_image2.png Greyscale Patent claim 5 depends from patent claim 1 and recites wherein said SGRM is PNG media_image3.png 170 194 media_image3.png Greyscale The difference between the patent claims and instant claims is that the instant claims are more broadly drawn to the treatment of an adrenal gland tumor. However, the instant claims would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention because ACC is an adrenal gland tumor. Claims 1-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 11,389,432 or claims 1-2 of U.S. Patent No. 11,234,971 in view of Greenstein et al. (WO2021/154750 A1)(hereinafter “Greenstein”). U.S. Patent No. 11,389,432 Patent claim 1 is drawn to a method of treating cancer in a cancer patient identified as likely to benefit from treatment with a GRM and cancer chemotherapy, the method comprising administering relacorilant. U.S. Patent No. 11,234,971 Patent claim 1 is drawn to a method of treating cancer in a cancer patient identified as likely to benefit from treatment with a GRM and cancer chemotherapy, the method comprising administering a GRM to said patient. Patent claim 2 recites wherein said GRM is relacorilant. The patent claims are silent regarding wherein the cancer is an adrenal gland tumor; however Greenstein teaches that relacorilant may be used in a method of reducing the size of an adrenal gland tumor, and Greenstein provides all claim limitations as was noted in the rejection above. The teachings of Greenstein are incorporated herein by reference. As a whole, Greenstein teaches that an adrenal gland tumor is a cancer likely to benefit from treatment with a GRM. The difference between the patent claims and the instant claims is that the instant claims are drawn to the treatment of an adrenal gland tumor (see paragraph [0012] of the instant specification: methods disclosed herein provide improved treatments for patients suffering from adrenal gland tumors). However, the instant claims would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention because Greenstein disclosed that relacorilant was useful for treating an adrenal gland tumor. One would have been motivated as a matter of practicing the patented invention. One would have had a reasonable expectation of success because a patient with an adrenal gland tumor, in view of Greenstein, would have been recognized as someone likely to benefit from the patented method. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN MARTIN whose telephone number is (571)270-0917. The examiner can normally be reached Monday - Friday 8 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. September 28, 2026 /K.S.M./Examiner, Art Unit 1624 /BRUCK KIFLE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

May 21, 2024
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §103, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788753
REPOSITIONING THE ANTI-LEPROSY DRUG CLOFAZIMINE AGAINST DRUG-RESISTANT MYELOMA AND PUTATIVE STEM-CELL SUBCLONES
3y 5m to grant Granted Nov 10, 2026
Patent 12790343
SOLID FORMS OF PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS
2y 6m to grant Granted Nov 10, 2026
Patent 12758629
N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT
4y 8m to grant Granted Oct 13, 2026
Patent 12746239
COMPOSITIONS AND METHODS COMPRISING ENDOTHELIN A RECEPTOR ANTAGONISTS AND ANDROGEN THERAPIES
4y 10m to grant Granted Sep 29, 2026
Patent 12747214
IMIDAZOLE-BASED SYNTHETIC LIPIDOIDS FOR IN VIVO MRNA DELIVERY INTO IMMUNE CELLS
4y 0m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
98%
With Interview (+20.7%)
Low
PTA Risk
Based on 161 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month